Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Reneo Pharmaceuticals Inc
(NQ:
RPHM
)
1.660
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Reneo Pharmaceuticals Inc
< Previous
1
2
Next >
RENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
May 14, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Reneo Pharmaceuticals, Inc. (Nasdaq – RPHM), ALLETE, Inc. (NYSE – ALE), Perficient, Inc. (Nasdaq – PRFT), Hibbett, Inc. (Nasdaq – HIBB)
May 13, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders
May 13, 2024
From
Halper Sadeh LLC
Via
Business Wire
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
May 13, 2024
From
Reneo Pharmaceuticals, Inc.; OnKure, Inc
Via
GlobeNewswire
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
May 07, 2024
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
March 28, 2024
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
March 25, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
December 14, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 13, 2023
Topline data results from the pivotal STRIDE study are expected in December 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
November 02, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
October 25, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
October 09, 2023
Topline data results from the STRIDE study are expected in December 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit
October 06, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
August 29, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results
August 10, 2023
Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with primary mitochondrial myopathies (PMM) due to mitochondrial DNA (mtDNA) defects, anticipated in 4Q23
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum
June 30, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices
June 26, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023
June 15, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
May 31, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
May 31, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results
May 11, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Announces Pricing of Public Offering of Common Stock
May 03, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock
May 03, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 27, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies
March 14, 2023
Topline data from the STRIDE study expected in the fourth quarter of 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023
March 09, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference
February 02, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)
January 31, 2023
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 08, 2022
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences
November 03, 2022
From
Reneo Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.